In silico screening of c-Met tyrosine kinase inhibitors targeting nucleotide and drug-substrate binding sites of ABCB1 as potential MDR reversal agents

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• NCI. Cancer Statistics 2021. Available from: https://www.cancer.gov/about-cancer/understanding/statistics.
   Google Scholar
• Robey RW, Pluchino KM, Hall MD, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452–464.
   PubMed Web of Science ®Google Scholar
• Chen Z, Shi T, Zhang L, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 2016;370(1):153–164.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.
   PubMed Web of Science ®Google Scholar
• Dlugosz A, Janecka A. ABC transporters in the development of multidrug resistance in cancer therapy. Curr Pharm Des. 2016;22(30):4705–4716.
   PubMed Web of Science ®Google Scholar
• Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors, in multi-drug resistance in cancer. In Methods in molecular biology. J. Zhou, Editor. 2010. Springer. 341–358.
   Google Scholar
• Waghray D, Zhang Q. Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment: miniperspective. J Med Chem. 2018;61(12):5108–5121.
   PubMed Web of Science ®Google Scholar
• Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights. 2013;7(1):27–34.
   PubMedGoogle Scholar
• Bugde P, Biswas R, Merien F, et al. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opin Ther Targets. 2017;21(5):511–530.
   PubMed Web of Science ®Google Scholar
• Kodan A, Yamaguchi T, Nakatsu T, et al. Inward-and outward-facing X-ray crystal structures of homodimeric P-glycoprotein CmABCB1. Nat Commun. 2019;10(1):1–12.
   PubMedGoogle Scholar
• Wilkens S. Structure and mechanism of ABC transporters. F1000Prime Rep. 2015;7:14–19.
   PubMedGoogle Scholar
• Metibemu DS, Akinloye OA, Akamo AJ, et al. Exploring receptor tyrosine kinases-inhibitors in cancer treatments. Egypt J Med Hum Genet. 2019;20(1):1–16.
   Google Scholar
• Zhao Y, Bilal M, Raza A, et al. Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer. Int J Biol Macromol. 2021;168:22–37.
   PubMed Web of Science ®Google Scholar
• Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):1–13.
   PubMedGoogle Scholar
• Jaramillo AC, Al Saig F, Cloos J, et al. How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance? CDR. 2018;1(1):6–29.
   Google Scholar
• Krchniakova M, Skoda J, Neradil J, et al. Repurposing tyrosine kinase inhibitors to overcome multidrug resistance in cancer: a focus on transporters and lysosomal sequestration. IJMS. 2020;21(9):3157.
   Google Scholar
• Koes DR, Baumgartner MP, Camacho CJ. Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J Chem Inf Model. 2013;53(8):1893–1904.
   PubMed Web of Science ®Google Scholar
• Alam A, Kowal J, Broude E, et al. Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science. 2019;363(6428):753–756.
   PubMed Web of Science ®Google Scholar
• O'Boyle NM, Banck M, James CA, et al. Open babel: an open chemical toolbox. J Cheminform. 2011;3(1):1–14.
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–1612.
   PubMed Web of Science ®Google Scholar
• Da Silva AWS, Vranken WF. ACPYPE-Antechamber python parser interface. BMC Res Notes. 2012;5(1):367–368.
   PubMedGoogle Scholar
• Fan Y-F, Zhang W, Zeng L, et al. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Lett. 2018;421:186–198.
   PubMed Web of Science ®Google Scholar
• Yang Y, Ji N, Cai C-Y, et al. Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor. Cancer Commun. 2020;40(7):285–300.
   Web of Science ®Google Scholar
• Zeng F, Wang F, Zheng Z, et al. Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo. Acta Pharm Sin B. 2020;10(5):799–811.
   PubMed Web of Science ®Google Scholar
• Dhasmana D, Singh A, Shukla R, et al. Targeting nucleotide binding domain of multidrug resistance-associated protein-1 (MRP1) for the reversal of multi drug resistance in cancer. Sci Rep. 2018;8(1):1–11.
   PubMedGoogle Scholar
• Gao M, Cui HR, Loe DW, et al. Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. J Biol Chem. 2000;275(17):13098–13108.
   PubMed Web of Science ®Google Scholar
• Wu S, Fu L. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Mol Cancer. 2018;17(1):25–25.
   PubMedGoogle Scholar
• Wu C-P, Hung T-H, Lusvarghi S, et al. The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochem Pharmacol. 2021;188:114516.
   PubMed Web of Science ®Google Scholar
• Cui Q, Cai C-Y, Gao H-L, et al. Glesatinib, a c-MET/SMO dual inhibitor, antagonizes P-glycoprotein mediated multidrug resistance in cancer cells. Front Oncol. 2019;9:313.
   PubMed Web of Science ®Google Scholar
• Schaeffer L. The role of functional groups in drug–receptor interactions, in the practice of medicinal chemistry. A.D. Wermuth CG, Raboisson P, Rognan D, Editor. San Diego: Elsevier; 2008. p. 359–378.
   Google Scholar
• Kumari R, Kumar R, Lynn A. g_mmpbsa-a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model. 2014;54(7):1951–1962.
   PubMed Web of Science ®Google Scholar